Jiangsu Bioperfectus Technologies Co., Ltd. (688399.SS)
CNY 64.67
(-0.06%)
CNY 64.67
(-0.06%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -255.06 Million CNY | -103.48% |
| 2022 | 2.25 Billion CNY | 82.35% |
| 2021 | 1.45 Billion CNY | 47.04% |
| 2020 | 933.05 Million CNY | 791.17% |
| 2019 | 108.35 Million CNY | 36.92% |
| 2018 | 79.08 Million CNY | 44.0% |
| 2017 | 62.74 Million CNY | 350.33% |
| 2016 | 22.1 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 1.97 Million CNY | 111.11% |
| 2024 Q2 | -17.77 Million CNY | -142.33% |
| 2024 Q1 | 34.69 Million CNY | 123.5% |
| 2023 FY | - CNY | -103.48% |
| 2023 Q1 | -14.32 Million CNY | -102.76% |
| 2023 Q2 | -30.75 Million CNY | -114.74% |
| 2023 Q4 | -41.26 Million CNY | 50.01% |
| 2023 Q3 | -82.54 Million CNY | -168.42% |
| 2022 Q4 | 517.98 Million CNY | 5.85% |
| 2022 Q3 | 489.35 Million CNY | -32.76% |
| 2022 Q2 | 727.71 Million CNY | -3.91% |
| 2022 FY | - CNY | 82.35% |
| 2022 Q1 | 757.33 Million CNY | 279.28% |
| 2021 Q3 | 589.14 Million CNY | 382.69% |
| 2021 Q1 | 466.18 Million CNY | 65.01% |
| 2021 FY | - CNY | 47.04% |
| 2021 Q4 | 199.67 Million CNY | -66.11% |
| 2021 Q2 | 122.05 Million CNY | -73.82% |
| 2020 Q3 | 316.98 Million CNY | 31.83% |
| 2020 Q2 | 240.44 Million CNY | 113.71% |
| 2020 Q1 | 112.5 Million CNY | 208.21% |
| 2020 FY | - CNY | 791.17% |
| 2020 Q4 | 282.51 Million CNY | -10.87% |
| 2019 FY | - CNY | 36.92% |
| 2019 Q4 | 36.5 Million CNY | 70.83% |
| 2019 Q3 | 21.36 Million CNY | 19.95% |
| 2019 Q1 | 15.19 Million CNY | -38.25% |
| 2019 Q2 | 17.81 Million CNY | 17.27% |
| 2018 Q4 | 24.59 Million CNY | -12.55% |
| 2018 FY | - CNY | 44.0% |
| 2018 Q3 | 28.12 Million CNY | 0.0% |
| 2017 FY | - CNY | 350.33% |
| 2016 FY | - CNY | 0.0% |